Patients often suffer multiple implantation failures before achieving a successful pregnancy.
The endometrial factor could be one of the possible causes of reproductive failure in many women who, even with the best embryo, do not achieve pregnancy.
The endometrial receptivity analysis or ERA, developed by Igenomix, can be essential to achieve pregnancy in these patients.
The information provided by the ERA test is key to determining whether the cause of implantation failure may be of endometrial origin, as approximately 3 out of 10 patients with recurrent implantation failure have a displaced window of implantation.
ERA is further supported by the data published in the randomized multicenter clinical trial showing that 56.2% of the patients who performed the ERA test had a baby after the personalized embryo transfer (pET) guided by the ERA results, compared to 42.4% who performed a transfer without the ERA test.
Therefore, performing a personalized embryo transfer (pET), according to the ERA predictor result, leads to improved live newborn rates.
Additionally, 71% of patients who performed a personalized embryo transfer had a baby after one year, compared to 48.9% who performed a fresh transfer without the ERA test.
What is personalized embryo transfer (pET)?
A personalized embryo transfer (pET) is one that is performed at the moment when the endometrium is receptive.In most women the endometrium acquires the receptive phenotype after 120 hours of progesterone exposure. However,in 3 out of 10 women the window of implantation (receptivity period) openat a different time than expected.
Personalized transfer with ERA
Precision medicine focuses on individualized targeted treatment and is one of the advantages of the ERA test in terms of personalization of the endometrial factor in reproductive treatment.
A personalized embryo transfer (pET) is superior in results over the transfer of frozen or fresh blastocysts (5-day-old embryos) at conventional timing without personalization, according to studies developed by Igenomix.
The ERA test is based on the analysis of the expression of 248 genes in the endometrium, which allows us to know the receptivity status of the endometrium at the time of embryo transfer. This test, patented by Igenomix in 2009, determines the optimal moment to transfer the embryo in each case, truly bringing the personalization of the treatment to the reproduction clinic.
In addition to significantly improving pregnancy rates the ERA test offers a solution to thousands of patients for whom there was no other answer in the usual practice.
